BioCryst Pharmaceuticals, Inc. (BCRX) Posts Wider Q2 Loss; Provides Update

August 8, 2013 8:41 AM

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q2 EPS of ($0.23), $0.09 worse than the analyst estimate of ($0.14). Revenue for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found